Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 181 publications
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: May 26, 2026
Cell-free RNA Signatures Derived from the Tumor Microenvironment Predict Outcomes of CAR-T Therapy in Large B Cell Lymphoma.
Journal: medRxiv : the preprint server for health sciences
Published: March 27, 2026
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.
Journal: Nature medicine
Published: March 13, 2026
CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.
Journal: The Lancet. Haematology
Published: March 02, 2026
Durable remission of primary testicular diffuse large B-cell lymphoma with secondary cutaneous involvement with chimeric antigen receptor T-cell therapy.
Journal: JAAD case reports
Published: February 12, 2026
Axicabtagene ciloleucel demonstrates superior outcomes over historically available treatments in relapsed/refractory follicular lymphoma: 5-year comparative analysis between ZUMA-5 and SCHOLAR-5.
Journal: Leukemia & lymphoma
Published: December 30, 2025
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.
Journal: Journal of hematology & oncology
Published: December 30, 2025
Safety and Tolerability of CAR T-Cell Therapy in Patients With End-Stage Kidney Disease on Hemodialysis: A Case Series.
Journal: Clinical lymphoma, myeloma & leukemia
Published: December 30, 2025
Antigen-IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2Rα.
Journal: Journal for immunotherapy of cancer
Published: December 12, 2025
eGFR Discordance and Its Association with Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell Therapies.
Journal: Journal of the American Society of Nephrology : JASN
Published: November 20, 2025
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 16, 2025
Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis.
Journal: Transplantation and cellular therapy
Published: August 12, 2025
Last Updated: 09/26/2026